Detailed Information

Cited 1 time in webofscience Cited 1 time in scopus
Metadata Downloads

Height outcomes in Korean children with idiopathic short stature receiving growth hormone treatmentopen access

Authors
Chae, Hyun WookHwang, Il-TaeLee, Ji-EunSo, Cheol HwanRhie, Young-JunLim, Jung SubKwon, Eun ByulYi, Kyung HeeKim, Eun YoungJo, Chae-KuShim, Kye ShikGil, Ha-YeongSeong, Min-JeongNam, Chung MoMoon, Ji-SuHwang, Jin Soon
Issue Date
Sep-2022
Publisher
Frontiers Media S.A.
Keywords
ISS (idiopathic short stature); growth hormone; height velocity; Korean ISS (idiopathic short stature) patients; dose of growth hormone; GH device type
Citation
Frontiers in Endocrinology, v.13
Indexed
SCIE
SCOPUS
Journal Title
Frontiers in Endocrinology
Volume
13
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/61631
DOI
10.3389/fendo.2022.925102
ISSN
1664-2392
1664-2392
Abstract
Objectives: Growth hormone (GH) therapy’s capacity to increase height velocity and height at the end of the study in children with idiopathic short stature (ISS) is controversial. We aimed to investigate the height standard deviation score (SDS) and height velocity of patients with ISS in Korea who received GH treatment. Methods: We retrospectively reviewed and performed linear mixed model and survival analyses on data from 12 tertiary hospitals in Korea, including subjects diagnosed with ISS from January 2009 to September 2019, treated with GH therapy for more than 6 months, and who were at a pre-pubertal state at the time of diagnosis. Results: We included 578 children (330 boys and 248 girls). The mean daily dose of GH in this study was 0.051 mg/kg, which was lower than the approved dose in Korea of 0.062 - 0.067 mg/kg. Height SDS was higher in patients who started treatment before the age of 6 years. The probability of reaching the target SDS (-1 SDS) from the beginning of treatment to 2–3 years after its start was higher in children starting treatment before the age of 6 years. The hazard ratio to reach the target SDS (-1 SDS) when using automatic pen or electronic devices was 1.727 times higher than that when using the needle and syringe device. Conclusion: ISS patients should start GH treatment at an early age, and even lower-than-recommended drug doses may be effective. The selection of automatic pen or electronic device can have a positive effect on reaching the target height SDS.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Pediatrics > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Rhie, Young Jun photo

Rhie, Young Jun
Ansan Hospital (Department of Pediatrics, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE